Retatrutide
Retatrutide is supplied by White Label Peptides as a lyophilised powder in multi-dose vials, for laboratory and research use, to business buyers only. It sits in our weight loss category. Every batch is verified by HPLC and ships with its own Certificate of Analysis.
| Compound | Retatrutide |
|---|---|
| Classification | GLP-1 / GIP / Glucagon Receptor Agonist |
| Molecular formula | C221H342N46O68 |
| Molecular weight | Approximately 4731 g/mol |
| Sequence | Glycine - Histidine - Lysine bound to Copper (Cu²⁺) |
| Structure | Synthetic multi-receptor peptide engineered to target: GLP-1 receptors GIP receptors Glucagon receptors |
| Form | Lyophilised powder (vials) or ready-to-use solution (pre-filled pens) |
| Appearance | White to off-white lyophilised powder prior to reconstitution |
| Presentation | Vials: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg. Pre-filled pens: 10 mg, 15 mg, 20 mg, 40 mg |
| Reconstitution | Typically reconstituted using: Bacteriostatic water - Sterile laboratory-grade water |
| Storage | Store refrigerated at 2-8°C in a cool, dry environment away from direct sunlight. Long-term storage may require freezing conditions prior to reconstitution. |
Specification data is provided for identification and procurement. It is not dosing guidance and it is not a claim of any effect.
Evidence and status
- Lab work
- Animal studies
- Human studies
- Approved label
Reviewed 2026-08-26. Regulatory status is stated for procurement and varies by market. It is not legal advice.
Research
What the published literature examined
The phase 2 obesity trial was double-blind, randomised and placebo-controlled in adults with a body mass index at or above 30, or 27 to under 30 with at least one weight-related condition, measuring percentage change in body weight over 48 weeks. A phase 2a substudy in metabolic dysfunction-associated steatotic liver disease randomised participants to 1, 4, 8 or 12 mg weekly or placebo and measured relative change in liver fat at 24 weeks. The phase 3 TRIUMPH programme comprises four randomised double-blind trials in more than 5,800 participants, with endpoints spanning obesity, obstructive sleep apnoea and knee osteoarthritis pain, plus a separate cardiovascular and kidney outcomes trial.
What is not established
No regulator anywhere has assessed retatrutide for any indication, so there is no approved label, no labelled route, no labelled dose, no labelled population and no regulator-reviewed interaction or long-term safety profile. Everything known about it comes from sponsor-run trials, several of them still running and unreported.
What distinguishes Retatrutide
It is a single peptide with agonist activity at three receptors, adding the glucagon receptor to GIP and GLP-1. No approved product and nothing else in this range carries glucagon receptor agonism. Its phase 3 programme is also unusual in scope for a metabolic peptide, pursuing obstructive sleep apnoea and knee osteoarthritis pain as registrational indications in their own right rather than as secondary endpoints inside a weight trial.
Sources
- ClinicalTrials.gov. TRIUMPH-1, NCT05929066, phase 3, 2,335 participants
- ClinicalTrials.gov. TRIUMPH-3, NCT05882045
- ClinicalTrials.gov. TRIUMPH-Outcomes, NCT06383390, cardiovascular and kidney outcomes
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity, a phase 2 trial
- Rationale and design of the TRIUMPH registrational clinical trials
This page describes a compound as a material and summarises published research about it. It is for general and procurement information only. It is not medical advice, not a treatment recommendation, and not guidance on use. Supplied for laboratory and research use, not for human consumption.
Specification
About this compound
The specification below is the batch-independent data. Purity and analysis date vary by batch, so they appear on the certificate issued with your order rather than on this page.
What this compound is
Retatrutide in supply terms
Retatrutide is identified by the molecular formula C221H342N46O68 and a molecular weight of approximately 4731 g/mol, among the heavier synthetic peptides in the catalogue. Its structure is built around three receptor-binding domains, which is the basis for its classification label, GLP-1 / GIP / Glucagon Receptor Agonist. That three-part name is a categorisation convention describing binding architecture, distinguishing it from single-receptor peptides in procurement records and specification sheets. It is supplied as a lyophilised powder in multi-dose research vials for injectable research format, appearing white to off-white before reconstitution. The catalogue carries four fill sizes, 5mg, 10mg, 15mg and 50mg, a wider spread than most single-target peptides in this range and worth noting when comparing unit pricing across suppliers. Reconstitution is typically carried out using bacteriostatic water or sterile laboratory-grade water. Cold-chain handling follows the standard band for the catalogue: refrigerated storage at 2-8C, away from direct sunlight, with freezing recommended for extended storage ahead of reconstitution. Certificate of Analysis documentation accompanies each order and stands as the definitive reference for the batch's verified storage and purity parameters, rather than general handling notes.
This section describes the compound as a material. It makes no claim about any effect and is not guidance on use.
What varies by batch
The page identifies the compound. The certificate records the batch.
Purity, method, analysis date and issuing party belong on the batch record rather than in page copy.
| Send the volume you need for Retatrutide and your delivery country. We will quote against it. | Request pricing |
Same category
Also in Weight Loss
| Compound | Identifier | Presentation |
|---|---|---|
| AOD-9604 | 221231-10-3 | Vials: 5 mg. Pre-filled pens: 5 mg |
| Cagrilintide | C194H312N54O59 | Vials: 5 mg, 10 mg. Pre-filled ... |
| Semaglutide | 910463-68-2 | Vials: 2 mg, 5 mg, 10 mg, 15 mg... |
| Tirzepatide | 2023788-19-2 | Vials: 5 mg, 10 mg, 15 mg, 20 m... |
Questions
Supply, answered
Is Retatrutide available for private label?
Yes. It can be supplied under your own brand on the vial and the carton, with the Certificate of Analysis issued under your product name.
What is the minimum order quantity?
Set for this compound specifically and confirmed at the enquiry stage, before you commit.
What purity is supplied?
98 percent or higher, verified by HPLC. The certificate issued with your batch carries the actual figure for that batch.
How is it shipped?
As lyophilised powder in multi-dose vials, packed for transit. Delivery in 5 to 7 days once the batch is released.
We already buy Retatrutide. Can you quote against our current volume?
Yes. Send the volume and the delivery country. Pricing is tiered per compound, so the quote reflects what you buy rather than a list price.
Can you supply Retatrutide as a second source?
Yes. Terms are agreed per compound, so you can add Retatrutide without moving anything else you buy elsewhere.
Request pricing for Retatrutide
Indicative volume and delivery country is enough to start. We reply within one working day.